Matt is a cross-functional biotech leader and entrepreneur with well over a decade of drug discovery and business development experience.
Prior to joining Bionomics, he was part of the founding team of Vigil Neuroscience where he led business development and played a critical role in the company’s strategic growth, private and public financings and the advancement of the programs into the clinic. Matt worked in management positions at Ipsen as part of the Global External Innovation and Partnering team where he was involved in several successful transactions. Matt’s career began as a scientist where he made significant contributions to the discovery and development of next generation therapeutics such as the KRAS inhibitors currently being developed by Revolution Medicines, Fog Pharma’s Beta-catenin/TCF4 inhibitor and several immunology antibody and nanobody programs at Sanofi.
Matt graduated with honors from Northeastern University earning his B.Sc. in Cell and Molecular Biology with minors in Psychology and Business Administration. Matt earned his M.B.A. from Babson College, a certificate in General Management from Stanford University Graduate School of Business and is an author and inventor on over 10 publications and patents.